SPRING1

Across TCGA pan-cancer cohorts, SPRING1 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of SPRING1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SPRING1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SPRING1 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

BLCA, LUAD, and LUSC are the cancer types where SPRING1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPRING1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	+0.826	<.001	10	view →
LUAD	Female	II,III,IV	−1.580	<.001	9	view →
LUSC	Female	II,III,IV	−1.538	<.001	8	view →
STAD	Male	II,III,IV	+1.144	<.001	8	view →
LIHC	All	II,III,IV	+1.105	<.001	8	view →
HNSC	All	III,IV	+0.586	<.001	8	view →
BRCA	All	II,III,IV	+0.455	<.001	8	view →
UCEC	All	III,IV	+1.364	.001	6	view →
CHOL	Male	All	+3.270	<.001	5	view →
THCA	All	All	+0.440	.006	3	view →
READ	All	III,IV	+0.605	.024	2	view →
KIRC	Male	II,III,IV	−0.360	.034	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

SPRING1–BLCA

Open the BLCA breakdown →